IPF patients may have a lower risk for original COVID-19 infection due to lower expression in AT2 cells but may have a higher risk for severity due to a broader expression spectrum of TMPRSS2. Further investigation and validation on these cell types are required. The gene discussed is TMPRSS2; the disease is idiopathic pulmonary fibrosis.